argenx SE Q3 2026 Earnings Recap

ARGX Q3 2026 Published October 25, 2026

Get alerts when ARGX reports next quarter

Shares fell 1.8% after earnings, a roughly flat reaction. The quarter showed continued revenue growth, while management emphasized future launches and pipeline milestones rather than offering a new outlook in the provided transcript.

Market Reaction

Post-Earnings -1.84%

See ARGX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter.
U.S. product net sales were $1.5 billion, up 16% quarter over quarter; gross-to-net deductions were 22%, in line with company expectations.
Management expects five potential launches in 2027, including pediatric and ocular MG opportunities, an auto-injector, and potential launches across other programs.
Argenx expects to file an sBLA for VYVGART in IMNM by year-end and anticipates the EMPASSION Phase III readout in MMN in December.
FB102 reported positive Phase II results in celiac disease and is ready to advance into Phase III.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ARGX on AllInvestView.